MENU
Insights
Home > Insights > OSTEOARTHRITIS AND VISCOSUPPLEMENTATION – Advertorial – Chemistry today

OSTEOARTHRITIS AND VISCOSUPPLEMENTATION – Advertorial – Chemistry today

Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY .

Read the Whole Interview
Related Articles
+
24.03.2025
LOS DESAFÍOS Y LAS OPORTUNIDADES DEL MERCADO FARMACÉUTICO JAPONÉS
Las principales tendencias que se deben tener en cuenta cuando se intenta entrar en el mercado farmacéutico japonés.
+
24.03.2025
CHALLENGES AND OPPORTUNITIES OF THE JAPANESE PHARMACEUTICAL MARKET
Here are the main trends that cannot be ignored when approaching the Japanese pharmaceutical market.
+
11.03.2025
IBSA – Presenta innovación y excelencia en CPhI Japan 2025
Con IBSA, la ciencia, la tecnología avanzada, la investigación y un enfoque centrado en el paciente serán protagonistas, también este año, en el CPhI Japan del 9 al 11 de abril de 2025.
We’re looking for partners and international distributors for our products.
GET IN TOUCH WITH US
You are now leaving the BUSINESSDEVELOPMENT. IBSAGROUP.COM website
This link will take you to a website to which our Policies do not apply. You are solely responsible for your interactions with that website.
Proceed
Cancel
Reserved document
Please, contact us , to receive the IBSA Product Catalogue
Contact us
Cancel
Confidential content
For more information about this product contact us
Contact us
Cancel
GET IN TOUCH WITH US
logo-footer

Headquarter

 

Via del Piano 29,
6926 Collina d’Oro,
Switzerland
Tel. +41 58 360 10 00

 

 

Follow us

Linkedin
Facebook
Youtube

Home Page
Licensing
Technologies
Documents
Insights
Contact